Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Peter S Hamblin und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
To investigate the utilization and costs of non‐insulin glucose‐lowering drugs (GLDs) in Australia from 2013 to 2023. Materials and Methods We conducted a retrospective analysis of the Australian Pharmaceutical Benefits Scheme (PBS) administrative dataset of 118 727 494 GLD prescriptions. The main outcome measures were the annual number of GLD prescriptions dispensed, accounting for type 2 diabetes mellitus (T2DM) prevalence and healthcare system costs, adjusted for inflation.
Results
Utilization of GLDs doubled from 6.4 million prescriptions in 2013 to 15.6 million in 2023. The average annual percent increase in utilization was 8.1%, compared to the average annual increase in prevalence of T2DM of 1.8%. The biggest change was in sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, for which there was an average annual increase in utilization of 59.4% (95% confidence interval [CI] 51.7%, 68.2%; p < 0.05) from 2014 (first full year of PBS listing), followed by glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), which showed an increase of 31.4% (95% CI 28.5%, 33.8%; p < 0.05) annually (2013 to 2023). Dipeptidyl peptidase‐4 inhibitor utilization tripled, with an average annual increase of 10.9% (95% CI 8.1%, 13.8%; p < 0.05), but this plateaued from 2020. Metformin utilization increased by 4.7% (95% CI 2.0%, 6.9%; p < 0.05) annually. In contrast, sulphonylurea, glitazone and acarbose utilization declined. Total GLD costs increased threefold over the same period. Despite only accounting for 11.7% of utilization, GLP‐1RAs contributed to 35% of the costs.
Conclusion
Utilization of GLDs doubled, and associated costs tripled over the past 11 years, with no sign of either utilization or costs plateauing, predominantly due to increased GLP‐1RA and SGLT2 inhibitor prescribing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Department of Endocrinology & Diabetes, Alfred Health, Melbourne, Victoria, Australia.
- Department of Endocrinology & Diabetes, Western Health, St Albans, Victoria, Australia.
ORCID-Profile: Peter S Hamblin, Arul Earnest, Anthony W Russell, Stella Talic, Ella Zomer, Sophia Zoungas
Zitieren
APA
Hamblin, P. S., Earnest, A., Russell, A. W., Talic, S., Zomer, E., & Zoungas, S. (2024). Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15893
Vancouver
Hamblin PS, Earnest A, Russell AW, Talic S, Zomer E, Zoungas S. Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15893
BibTeX
@article{Hamblin2024,
author = {Hamblin, Peter S and Earnest, Arul and Russell, Anthony W and Talic, Stella and Zomer, Ella and Zoungas, Sophia},
title = {Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15893}
}
EUVIMED